Scholar Rock director Akkaraju buys $12 million in shares By Investing.com

Scholar Rock (SRRK) Stock Looks Overvalued Against Its Book Value

Scholar Rock Receives FDA's Priority Review Voucher For Isembyld

Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMA Resubmission for Apitegromab Might Change The Case For Investing In Scholar Rock Holding (SRRK)

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock Refiles Marketing Authorisation Application With EMA For Apitegromab To Treat Children And Adults With Spinal Muscular Atrophy

Scholar Rock (NASDAQ:SRRK) Stock Price Up 2.8% - Should You Buy?

$SRRK stock is down 9% today. Here's what we see in our data.

Scholar Rock Holding Reports Q2 2026 Results: Full Earnings Call Transcript

3 drug targets pharma is betting on next

FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals

Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says

This week in charts: GSK’s China deals, the $300M IPO club and selling the news